Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT 105 versus PLEGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT 105 versus PLEGINE.
MELFIAT-105 vs PLEGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting reuptake of serotonin at the presynaptic neuronal membrane.
Plegine (phendimetrazine) is a sympathomimetic amine that acts as an anorectic agent. It stimulates the hypothalamus to release norepinephrine and dopamine, thereby suppressing appetite. The exact mechanism is thought to involve the release of catecholamines from presynaptic nerve terminals in the lateral hypothalamic feeding center, leading to decreased food intake.
105 mg orally once daily in the morning.
25-50 mg orally once daily at bedtime, maximum 100 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 hours, supporting twice-daily dosing in clinical practice.
Terminal elimination half-life: 4–8 hours (mean 6 hours). Clinical context: Steady-state achieved after 24–48 hours of repeated dosing.
Approximately 90% of an administered dose is excreted renally as unchanged drug and metabolites, with the remainder eliminated via biliary/fecal routes.
Renal: 40% unchanged; Hepatic metabolism: 60% (biliary/fecal elimination of metabolites).
Category C
Category C
Anorexiant
Anorexiant